• Home
  • Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Author List
Kieuhoa Tran Vo, Jennifer Gibney Michlitsch, Avanthi T Shah, Janel Long-Boyle, Mi-Ok Kim, Clay Gustafson, Alejandro Sweet-Cordero, Katherine K. Matthay, Steven G. DuBois
Publication
Journal of Clinical Oncology
Publication ID (Profile URL)
https://researcherprofiles.org/profile/79292281
Publication Year
2018
Publication Title
Kieuhoa Tran Vo, Jennifer Gibney Michlitsch, Avanthi T Shah, Janel Long-Boyle, Mi-Ok Kim, Clay Gustafson, Alejandro Sweet-Cordero, Katherine K. Matthay, Steven G. DuBois. Phase 1 multicenter trial to assess the maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma. Journal of Clinical Oncology. 2018 May 20; 36(15_suppl):tps10576-tps10576.